Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin

AIMS: To assess whether people with type 2 diabetes transferring from higher basal insulin doses (> 20 units) to a starting dose of 16 units of insulin degludec/liraglutide (IDegLira) benefit from IDegLira with/without transient loss of glycaemic control. METHODS: Post hoc analysis of DUAL V and...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Diabet Med
Päätekijät: Meneghini, L., Doshi, A., Gouet, D., Vilsbøll, T., Begtrup, K., Őrsy, P., Ranthe, M. F., Lingvay, I.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Research Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7003817/
https://ncbi.nlm.nih.gov/pubmed/31705547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dme.14178
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia